LamdaGen Corporation, a nano-technology platform company that provides plasmonic sensors and systems for diagnostics and life sciences, announced the United State Patent and Trademark Office (USTPO) issuance of patent “Enzymatic Assays for LSPR” for performing quantitative diagnostics via Localized Surface Plasmon Resonance (LSPR).
The patent claims broadly cover plasmonic surfaces and nano-particles used for LSPR-oriented ELISA. The Company’s proprietary LSPR metallic thin-films are easily grown onto practically any solid support, thereby allowing compatibility with a wide range of current IVD systems — including plate-based throughput platforms and rapid diagnostic systems for Point-of-Care.
“Our plasmonic ELISA provides for rapid quantitative detection with excellent reproducibility at sensitivity levels exceeding conventional ELISAs by as much as four orders of magnitude,” commented Randy Storer, CEO and Co-Founder of LamdaGen Corporation. “The issuance of this patent illustrates LamdaGen’s unique ability to harness modern plasmonics for advancing In-Vitro Diagnostics (IVD).”
This patent is the latest addition to LamdaGen’s growing global IP portfolio for plasmonic-based nano-applications in diagnostics, contaminant-monitoring and life science research.
About LamdaGen Corporation
LamdaGen is a nano-technology platform company providing plasmonic sensors and analytical systems for diagnostic and life science markets. The company’s Localized Surface Plasmon Resonance (LSPR) sensors and systems enable real-time detection of biomolecular interactions, as well as enzymatic and chemical reactions. LamdaGen is a privately held company headquartered in Menlo Park, California and is the first to offer commercial LSPR products. For more information, visit www.lamdagen.com or email email@example.com